Value of ultrasound combined with MRI in the diagnosis of primary and recurrent hepatocellular carcinoma

Ji,Xiaoli; Zhou,Shisheng; Yang,Peng; Liu,Faqin; Li,Yan; Li,Hong

doi:10.3892/ol.2019.10945

Value of ultrasound combined with MRI in the diagnosis of primary and recurrent hepatocellular carcinoma

Authors:
- Xiaoli Ji
- Shisheng Zhou
- Peng Yang
- Faqin Liu
- Yan Li
- Hong Li
View Affiliations

Affiliations: Department of Special Inspection (Ultrasound in Obstetrics and Gynecology), Qingdao Women and Children's Hospital, Qingdao, Shandong 266034, P.R. China, Department of Ultrasound, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China, Administrative Department (Outpatient), The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China, Department of Operating Room, The People's Hospital of Zhangqiu Area, Jinan, Shandong 250200, P.R. China, Department of Ultrasound, Jining No. 1 People's Hospital, Jining, Shandong 272111, P.R. China
Published online on: October 2, 2019 https://doi.org/10.3892/ol.2019.10945
Pages: 6180-6186
Copyright: © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ultrasound (US) combined with magnetic resonance imaging (MRI) in the diagnosis of primary hepatocellular carcinoma (PHCC) and recurrent hepatocellular carcinoma (RHCC) were compared. The clinical data of 329 patients with hepatocellular carcinoma (HCC) admitted to Qingdao Women and Children's Hospital from June 2015 to December 2017 were collected. One hundred and sixty patients with PHCC were regarded as the PHCC group, and the other 169 patients with RHCC were regarded as the RHCC group. US and MRI were used in the imaging diagnosis of both groups and the results of US combined with MRI, US, and MRI alone were compared. The lesion size in the PHCC group was significantly higher than that in the RHCC group (P<0.05). The MRI fast‑in and fast‑out rates of the two groups were significantly higher than those of the other three methods (P<0.05). The coincidence rate of MRI in the two groups was higher than that of computed tomography (CT), US, and US combined with MRI (P<0.05). The coincidence rates of CT, US, MRI, and US combined with MRI in PHCC group were significantly higher than those in RHCC group. In PHCC group, MRI was superior to the other methods in the detection of micro HCC (P<0.05). In RHCC group, MRI was significantly better than US in the detection of micro HCC (P<0.05). The sensitivity, specificity, positive predictive value and negative predictive value of MRI were significantly better than the other three methods (P<0.05). MRI alone has the best diagnostic efficacy for micro HCC‑type lesions. The diagnostic efficacy of MRI, US, CT, and US combined with MRI in PHCC was better than those in RHCC. In addition to imaging examination, the diagnosis of RHCC should be combined with other indicators for comprehensive diagnosis.

View Figures

View References

1	Hu Z, Zhou J, Xu X, Li Z, Zhou L, Wu J, Zhang M and Zheng S: Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One. 7:e365872012. View Article : Google Scholar : PubMed/NCBI
2	Yang YY, Wang SJ, Yang LY, Lirng JF, Huang CC, Liang JF, Lee FY, Hwang SJ, Huang CC and Kirby R: Effects of a new parallel primary healthcare centre and on-campus training programme on history taking, physical examination skills and medical students' preparedness: A prospective comparative study in Taiwan. BMJ Open. 7:e0162942017. View Article : Google Scholar : PubMed/NCBI
3	Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J and Committee G; Guideline Committee, : Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 22:9279–9287. 2016. View Article : Google Scholar : PubMed/NCBI
4	Rojas A, Zhang P, Wang Y, Foo WC, Muñoz NM, Xiao L, Wang J, Gores GJ, Hung MC and Blechacz B: A positive TGF-β/c-KIT feedback loop drives tumor progression in advanced primary liver cancer. Neoplasia. 18:371–386. 2016. View Article : Google Scholar : PubMed/NCBI
5	Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
6	Rubin J, Ayoub N, Kaldas F and Saab S: Management of recurrent hepatocellular carcinoma in liver transplant recipients: A systematic review. Exp Clin Transplant. 10:531–543. 2012. View Article : Google Scholar : PubMed/NCBI
7	Oliva MR and Saini S: Liver cancer imaging: role of CT, MRI, US and PET. Cancer Imaging. 4:S42–S46. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chen Q, Shang W, Zeng C, Wang K, Liang X, Chi C, Liang X, Yang J, Fang C and Tian J: Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes. Oncotarget. 8:32741–32751. 2017.PubMed/NCBI
9	Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB and Davis GL: Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 26:1187–1194. 2007. View Article : Google Scholar : PubMed/NCBI
10	Dumitrescu CI, Gheonea IA, Săndulescu L, Surlin V, Săftoiu A and Dumitrescu D: Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Med Ultrason. 15:261–267. 2013. View Article : Google Scholar : PubMed/NCBI
11	Sun X, Li RU, Zhang B, Yang Y and Cui Z: Treatment of liver cancer of middle and advanced stages using ultrasound-guided percutaneous ethanol injection combined with radiofrequency ablation: A clinical analysis. Oncol Lett. 11:2096–2100. 2016. View Article : Google Scholar : PubMed/NCBI
12	Shi J, Liu TW, Chen J, Green D, Jaffray D, Wilson BC, Wang F and Zheng G: Transforming a targeted porphyrin theranostic agent into a PET imaging probe for cancer. Theranostics. 1:363–370. 2011. View Article : Google Scholar : PubMed/NCBI
13	Huang L, Li GM, Zhu JY, Li Z, Li T and Leng XS: Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: A preliminary study. OncoTargets Ther. 5:457–462. 2012. View Article : Google Scholar
14	Malagari K, Pomoni M, Sotirchos VS, Moschouris H, Bouma E, Charokopakis A, Kelekis AD, Koundouras D, Filippiadis D, Chatziioannou A, et al: Long term recurrence analysis post drug eluting bead (deb) chemoembolization for hepatocellular carcinoma (hcc). Hepatogastroenterology. 60:1413–1419. 2013.PubMed/NCBI
15	Lee CH, Brubaker LM, Gerber DA, Ku YM, Kim YH, Shin SS and Semelka RC: MRI findings of recurrent hepatocellular carcinoma after liver transplantation: Preliminary results. J Magn Reson Imaging. 33:1399–1405. 2011. View Article : Google Scholar : PubMed/NCBI
16	Le Moigne F, Durieux M, Bancel B, Boublay N, Boussel L, Ducerf C, Berthezène Y and Rode A: Impact of diffusion-weighted MR imaging on the characterization of small hepatocellular carcinoma in the cirrhotic liver. Magn Reson Imaging. 30:656–665. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bruix J, Reig M and Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016. View Article : Google Scholar : PubMed/NCBI
18	Hu Z, Lv G, Li Y, Li E, Li H, Zhou Q, Yang B and Cao W: Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound. J Exp Clin Cancer Res. 35:712016. View Article : Google Scholar : PubMed/NCBI
19	Furlan A, Marin D, Cabassa P, Taibbi A, Brunelli E, Agnello F, Lagalla R and Brancatelli G: Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: Intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. Eur J Radiol. 81:2099–2105. 2012. View Article : Google Scholar : PubMed/NCBI
20	Wakayama K, Kamiyama T, Yokoo H, Orimo T, Shimada S, Einama T, Kamachi H and Taketomi A: Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection. J Surg Oncol. 115:324–329. 2017. View Article : Google Scholar : PubMed/NCBI
21	Yang X, Wang D, Ma Y, Zhao Q, Fallon JK, Liu D, Xu XE, Wang Y, He Z and Liu F: Theranostic nanoemulsions: Codelivery of hydrophobic drug and hydrophilic imaging probe for cancer therapy and imaging. Nanomedicine (Lond). 9:2773–2785. 2014. View Article : Google Scholar : PubMed/NCBI
22	Escartin A, Sapisochin G, Bilbao I, Vilallonga R, Bueno J, Castells L, Dopazo C, Castro E, Caralt M and Balsells J: Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 39:2308–2310. 2007. View Article : Google Scholar : PubMed/NCBI
23	Xiao JD, Zhu WH and Shen SR: Evaluation of hepatocellular carcinoma using contrast-enhanced ultrasonography: Correlation with microvessel morphology. Hepatobiliary Pancreat Dis Int. 9:605–610. 2010.PubMed/NCBI
24	Shagdarsuren B, Tamai H, Shingaki N, Mori Y, Maeshima S, Nuta J, Maeda Y, Moribata K, Niwa T, Deguchi H, et al: Contribution of contrast-enhanced sonography with perfluorobutane microbubbles for diagnosis of recurrent hepatocellular carcinoma. J Ultrasound Med. 35:1383–1391. 2016. View Article : Google Scholar : PubMed/NCBI
25	Nörthen A, Asendorf T, Walson PD and Oellerich M: Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. Clin Biochem. 52:20–25. 2018. View Article : Google Scholar : PubMed/NCBI